## **Schedule of Accreditation**

issued by

## **United Kingdom Accreditation Service**

2 Pine Trees, Chertsey Lane, Staines-upon-Thames, TW18 3HR, UK



4385 Accredited to ISO/IEC 17043:2023

## **Quality Control for Molecular Diagnostics (QCMD)**

Issue No: 012 Issue date: 01 November 2024

Units 5 and 6 Technology Terrace West of Scotland Science Park

Glasgow Scotland G20 OXA Contact: Eilidh King
Tel: +44 (0)141 945 6474
Fax: +44 (0)141 945 5795
E-Mail: info@qcmd.org
Website: www.qcmd.org

Proficiency Tests provided from the above address only

#### **DETAIL OF ACCREDITATION**

Materials/Products	Scheme Name/Type of Test/Properties Measured	Scheme Protocols/Procedures/ Techniques Used
	Molecular Diagnostics	
	Identification and attributes of specific micro-organisms through the molecular detection, determination, quantification, genotyping and sequencing in the following categories disease areas:	Specific schemes/micro- organisms as described: Quality Control for Molecular Diagnostics (QCMD) current catalogue. (www.qcmd.org)
	Blood Borne Viruses	
Plasma	B19 virus	
Plasma, Synthetic Faecal Matrix	Hepatitis A virus	
Plasma	Hepatitis B virus	
Plasma	Hepatitis C virus	
Plasma	Hepatitis D virus	
Plasma	Hepatitis E virus	
Plasma	Human Immunodeficiency virus (HIV1)	
Plasma	Human Immunodeficiency virus (HIV2)	
Physiological Buffer	HIV DNA (Proviral)	
	Central Nervous System	
Transport Medium	Arthropod-Borne Viruses (multi-pathogen)	
Transport Medium, Plasma, Urine	BK virus	
Transport Medium, Microbiological Medium	Borrelia burgdorferi	
Transport Medium	Chikungunya virus	

Assessment Manager: AK2 Page 1 of 9



## United Kingdom Accreditation Service 2 Pine Trees, Chertsey Lane, Staines-upon-Thames, TW18 3HR, UK

## **Quality Control for Molecular Diagnostics (QCMD)**

Issue No: 012 Issue date: 01 November 2024

#### Proficiency Tests provided from main address only

Materials/Products	Scheme Name/Type of Test/Properties Measured	Scheme Protocols/Procedures/ Techniques Used
	Molecular Diagnostics (cont'd):	
	Identification and attributes of specific micro-organisms through the molecular detection, determination, quantification, genotyping and sequencing in the following categories disease areas: (cont'd)	Specific schemes/micro- organisms as described: Quality Control for Molecular Diagnostics (QCMD) current catalogue. (www.qcmd.org)
	Central Nervous System (cont'd):	
Synthetic CSF, Transport Medium	Central Nervous System I (Viral Meningitis and Encephalitis) (multi-pathogen)	
Synthetic CSF, Transport Medium	Central Nervous System II (Non-Viral Meningitis and Encephalitis) (multipathogen)	
Transport Medium	Dengue virus	
Transport Medium	Enterovirus	
Transport Medium	Herpes simplex virus	
Transport Medium, Plasma	JC virus	
Transport Medium	Measles / Mumps	
Transport Medium	Parechovirus	
Amniotic Fluid, Plasma, Synthetic Amniotic Fluid	Toxoplasma gondii	
Transport Medium	Varicella zoster virus	
Transport Medium	West Nile virus	
Transport Medium	Zika virus	
	Congenital Infections	
Plasma, Whole Blood, Dried Blood Spots (DBS)	Cytomegalovirus	
Amniotic Fluid, Plasma, Synthetic Amniotic Fluid	Toxoplasma gondii	

Assessment Manager: AK2 Page 2 of 9



## United Kingdom Accreditation Service 2 Pine Trees, Chertsey Lane, Staines-upon-Thames, TW18 3HR, UK

## **Quality Control for Molecular Diagnostics (QCMD)**

**Issue No:** 012 Issue date: 01 November 2024

#### Proficiency Tests provided from main address only

Materials/Products	Scheme Name/Type of Test/Properties Measured	Scheme Protocols/Procedures/ Techniques Used
	Molecular Diagnostics (cont'd):	
	Identification and attributes of specific micro-organisms through the molecular detection, determination, quantification, genotyping and sequencing in the following categories disease areas: (cont'd)	Specific schemes/micro- organisms as described: Quality Control for Molecular Diagnostics (QCMD) current catalogue. (www.qcmd.org)
	Drug Resistance	
Plasma	Cytomegalovirus	
Physiological Buffer Microbiological Medium	Extended Spectrum ß-lactamase and Carbapenemase	
Plasma	Hepatitis B virus	
Plasma	Hepatitis C virus	
Plasma	Herpes simplex virus	
Plasma	Human Immunodeficiency virus (HIV)	
Microbiological Medium, Transport Medium	Methicillin resistant Staphylococcus aureus	
Sputum, Synthetic Sputum, Synthetic CSF	Mycobacterium tuberculosis Drug Resistance	
Microbiological Medium Transport Medium	Vancomycin Resistant Enterococci	
	Exotic / Emerging Diseases	
Transport Medium	Arthropod-Borne Viruses (multi-pathogen)	
Transport Medium	Chikungunya virus	
Transport Medium	Dengue virus	
Transport Medium	Middle Eastern Respiratory Syndrome (MERS) Coronavirus	
Transport Medium	SARS-CoV-2	
Transport Medium	West Nile virus	

Assessment Manager: AK2 Page 3 of 9



## United Kingdom Accreditation Service 2 Pine Trees, Chertsey Lane, Staines-upon-Thames, TW18 3HR, UK

## **Quality Control for Molecular Diagnostics (QCMD)**

**Issue No:** 012 Issue date: 01 November 2024

#### Proficiency Tests provided from main address only

Materials/Products	Scheme Name/Type of Test/Properties Measured	Scheme Protocols/Procedures/ Techniques Used
	Molecular Diagnostics (cont'd):	
	Identification and attributes of specific micro-organisms through the molecular detection, determination, quantification, genotyping and sequencing in the following categories disease areas: (cont'd)	Specific schemes/micro- organisms as described: Quality Control for Molecular Diagnostics (QCMD) current catalogue. (www.qcmd.org)
	Exotic / Emerging Diseases (cont'd):	
Transport Medium	Yellow fever virus	
Transport Medium	Zika Virus	
	Gastrointestinal Diseases	
Transport Medium, Plasma, Synthetic Faecal Matrix	Adenovirus	
Synthetic Faecal Matrix, Transport medium, Microbiological Medium	Bacterial Gastroenteritis (multi-pathogen)	
Transport Medium, Synthetic Faecal Matrix	Clostridium difficile	
Synthetic Faecal Matrix, Physiological Buffer, Transport Medium, Microbiological Medium	Diarrheagenic Escherichia coli	
Synthetic Faecal Matrix Physiological Buffer	Helicobacter pylori	
Transport Medium, Physiological Buffer, Synthetic Faecal Matrix	Norovirus	
Synthetic Faecal Matrix, Transport medium, Microbiological Medium	Parasitic Gastroenteritis (multi-pathogen)	
Synthetic Faecal Matrix, Transport medium,	Viral Gastroenteritis (multi-pathogen)	

Assessment Manager: AK2 Page 4 of 9



## United Kingdom Accreditation Service 2 Pine Trees, Chertsey Lane, Staines-upon-Thames, TW18 3HR, UK

### **Quality Control for Molecular Diagnostics (QCMD)**

**Issue No:** 012 Issue date: 01 November 2024

#### Proficiency Tests provided from main address only

Proficiency Tests provided from main address only		
Materials/Products	Scheme Name/Type of Test/Properties Measured	Scheme Protocols/Procedures/ Techniques Used
	Molecular Diagnostics (cont'd):	
	Identification and attributes of specific micro-organisms through the molecular detection, determination, quantification, genotyping and sequencing in the following categories disease areas: (cont'd)	Specific schemes/micro- organisms as described: Quality Control for Molecular Diagnostics (QCMD) current catalogue. (www.qcmd.org)
	Immunocompromised Associated Diseases	
Plasma, Physiological Buffer, Synthetic Sputum	Aspergillus	
Transport Medium, Plasma, Urine	BK virus	
Plasma, Physiological Buffer, Synthetic BAL	Candida	
Plasma, Whole Blood, Dried Blood Spots (DBS)	Cytomegalovirus	
Plasma, Whole Blood	Epstein Barr virus	
Transport Medium, Plasma	Human Herpes virus 6	
Transport Medium, Plasma	JC virus	
Physiological Buffer	Pneumocystis jiroveci (PCP)	
Transport Medium, Plasma	Torque teno virus	
Amniotic Fluid, Plasma, Synthetic Amniotic Fluid	Toxoplasma gondii	
Plasma, Transport Medium	Transplantation (multi-pathogen)	
	Respiratory Diseases	
Transport Medium, Plasma, Synthetic Faecal Matrix	Adenovirus	
Transport Medium, Physiological Buffer	Atypical mycobacterium	

Assessment Manager: AK2 Page 5 of 9



## United Kingdom Accreditation Service 2 Pine Trees, Chertsey Lane, Staines-upon-Thames, TW18 3HR, UK

## **Quality Control for Molecular Diagnostics (QCMD)**

**Issue No:** 012 Issue date: 01 November 2024

#### Proficiency Tests provided from main address only

Materials/Products	Scheme Name/Type of Test/Properties Measured	Scheme Protocols/Procedures/ Techniques Used
	Molecular Diagnostics (cont'd):	
	Identification and attributes of specific micro-organisms through the molecular detection, determination, quantification, genotyping and sequencing in the following categories disease areas: (cont'd)	Specific schemes/micro- organisms as described: Quality Control for Molecular Diagnostics (QCMD) current catalogue. (www.qcmd.org)
	Respiratory Diseases (cont'd)	
Physiological Buffer, Transport Medium	Bordetella pertussis	
Transport Medium	Chlamydia psittaci	
Bronchoalveolar Lavage (BAL), Transport Medium	Chlamydophila pneumoniae	
Transport Medium	Coronavirus	
Transport Medium	Enterovirus	
Transport Medium	Human metapneumovirus	
Transport Medium	Influenza virus	
Bronchoalveolar Lavage (BAL), Transport Medium	Legionella pneumoniae	
Transport Medium	Measles / Mumps	
Transport Medium	Middle Eastern Respiratory Syndrome (MERS) Coronavirus virus	
Sputum, Synthetic Sputum, Synthetic CSF	Mycobacterium tuberculosis	
Bronchoalveolar Lavage (BAL), Transport Medium	Mycoplasma pneumoniae	
Transport Medium	Parainfluenza virus	
Physiological Buffer	Pneumocystis jiroveci (PCP)	
Transport Medium	Respiratory I (multi-pathogen)	
Transport Medium	Respiratory I plus (multi-pathogen)	

Assessment Manager: AK2 Page 6 of 9



## United Kingdom Accreditation Service 2 Pine Trees, Chertsey Lane, Staines-upon-Thames, TW18 3HR, UK

### **Quality Control for Molecular Diagnostics (QCMD)**

**Issue No:** 012 Issue date: 01 November 2024

#### Proficiency Tests provided from main address only

Materials/Products	Scheme Name/Type of Test/Properties Measured	Scheme Protocols/Procedures/ Techniques Used
	Molecular Diagnostics (cont'd):	
	Identification and attributes of specific micro-organisms through the molecular detection, determination, quantification, genotyping and sequencing in the following categories disease areas: (cont'd)	Specific schemes/micro- organisms as described: Quality Control for Molecular Diagnostics (QCMD) current catalogue. (www.qcmd.org)
	Respiratory Diseases (cont'd):	
Transport Medium	Respiratory II (multi-pathogen)	
Transport Medium	Respiratory III (multi-pathogen)	
Transport Medium	Respiratory syncytial virus	
Transport Medium	Rhinovirus	
Transport Medium	SARS-CoV-2	
	Sexually Transmitted Infections	
Transport Medium, Urine, Physiological Buffer	Chlamydia trachomatis	
Transport Medium	Herpes simplex virus	
Transport Medium (PreservCyt), Transport Medium (SurePath)	Human papillomavirus	
Transport Medium, Urine, Physiological Buffer	Mycoplasma genitalium	
Transport Medium, Urine, Physiological Buffer	Neisseria gonorrhoeae	
Urine, Physiological Buffer, Transport Medium	Syphilis	
Urine, Physiological Buffer, Transport Medium	Sexually Transmitted Infections I (multipathogen)	
Urine, Physiological Buffer, Transport Medium	Sexually Transmitted Infections II (multipathogen)	
Transport Medium, Urine, Physiological Buffer	Trichomonas vaginalis	

Assessment Manager: AK2 Page 7 of 9



ISO/IEC 17043:2023

## **Schedule of Accreditation** issued by

# United Kingdom Accreditation Service 2 Pine Trees, Chertsey Lane, Staines-upon-Thames, TW18 3HR, UK

## **Quality Control for Molecular Diagnostics (QCMD)**

**Issue No:** 012 Issue date: 01 November 2024

#### Proficiency Tests provided from main address only

Materials/Products	Scheme Name/Type of Test/Properties Measured	Scheme Protocols/Procedures/ Techniques Used
	Molecular Diagnostics (cont'd):	
	Identification and attributes of specific micro-organisms through the molecular detection, determination, quantification, genotyping and sequencing in the following categories disease areas: (cont'd)	Specific schemes/micro- organisms as described: Quality Control for Molecular Diagnostics (QCMD) current catalogue. (www.qcmd.org)
	Transplant Associated Diseases	
Transport Medium, Plasma, Synthetic Faecal Matrix	Adenovirus	
Transport Medium, Plasma, Urine	BK virus	
Plasma, Whole Blood, Dried Blood Spots (DBS)	Cytomegalovirus	
Transport Medium, Plasma, Whole Blood	Epstein Barr virus	
Transport Medium, Plasma	Human Herpes virus 6	
Transport Medium, Plasma	JC virus	
Transport Medium, Plasma	Torque teno virus	
Amniotic Fluid, Plasma, Synthetic Amniotic Fluid	Toxoplasma gondii	
Plasma, Transport Medium	Transplantation (multi-pathogen)	
	Other:	
Synthetic Faecal Matrix, Physiological Buffer	Dermatophytosis	
Plasma, Synthetic CSF, Transport Medium	Group B Streptococcus	
Physiological Buffer, Transport Medium	Mycoplasma spp. (cell contamination)	
Whole Blood, Plasma, Transport Medium	Sepsis	

Assessment Manager: AK2 Page 8 of 9



Accredited to ISO/IEC 17043:2023

### Schedule of Accreditation issued by

## United Kingdom Accreditation Service 2 Pine Trees, Chertsey Lane, Staines-upon-Thames, TW18 3HR, UK

## **Quality Control for Molecular Diagnostics (QCMD)**

**Issue No:** 012 Issue date: 01 November 2024

#### Proficiency Tests provided from main address only

Materials/Products	Scheme Name/Type of Test/Properties Measured	Scheme Protocols/Procedures/ Techniques Used
	Molecular Diagnostics (cont'd):  Identification and attributes of specific micro-organisms through the molecular detection, determination, quantification, genotyping and sequencing in the following categories disease areas: (cont'd)	Specific schemes/micro- organisms as described: Quality Control for Molecular Diagnostics (QCMD) current catalogue. (www.qcmd.org)
	Molecular Typing:	
Physiological Buffer	Bacterial 16S Ribosomal RNA	
Plasma	Cytomegalovirus	
Transport Medium	Enterovirus	
Plasma	Hepatitis B virus	
Plasma	Hepatitis C virus	
Plasma	Human Immunodeficiency virus (HIV)	
Transport Medium	Influenza virus	
Microbiological Medium, Transport Medium	Staphylococcus aureus (including MRSA)	
	Sequencing, Mass Spectrometry and other Typing Technologies	
Transport Medium Microbiological Medium Physiological Buffer	Microbial identification using Matrix- assisted laser desorption/ionization (MALDI-TOF)	
	SARS-CoV-2 Antigen Testing	
Inactivated Whole SARS-CoV-2 virus (including Variants of concern) within Transport Medium	SARS-CoV-2 Antigen	
END		

Assessment Manager: AK2 Page 9 of 9